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• PsA has an estimated prevalence of 0.3% to 1.0% in the general population and can result in joint damage, decreased physical function, and impaired activities of daily living and disability. [2] [3] [4] [5] • Effective treatment of PsA has been shown to improve patient-reported outcomes significantly. 6 • Apremilast is an oral phosphodiesterase 4 inhibitor that acts intracellularly to regulate inflammatory mediators. 7 • In 2015, the European Medicines Agency approved apremilast, alone or in combination with disease-modifying anti-rheumatic drugs (DMARDs), for the treatment of active PsA in adult patients who have had an inadequate response to or who have been intolerant of a prior DMARD therapy.
OBJECTIVE
• This study was designed to assess the cost-effectiveness of placing apremilast, a new oral treatment, before tumour necrosis factor-alpha (TNF-α) inhibitor therapies in PsA patients who have failed to respond to or are intolerant of conventional DMARD therapy, from a Scottish payer perspective.
METHODS

Model Structure
• A Markov state-transition cohort model was developed with a 28-day cycle length and a 40-year time horizon based on the Rodgers et al. (2011) 1 model ( Figure 1 ).
• Different treatment options were considered as mutually exclusive health states and describe the treatment pathway and the impact of each treatment option, as measured by the Psoriatic Arthritis Response Criteria (PsARC), at the end of the trial period, ranging from 12 to 16 weeks.
• The following treatment sequences were compared: (1) apremilast followed by adalimumab followed by etanercept and (2) adalimumab followed by etanercept.
• Patients failing etanercept received best supportive care (BSC) as the last line of treatment in both sequences.
• All-cause mortality, adjusted to reflect the increased risk of death associated with PsA, was included in all health states. 8 • A 16.5% all-cause annual dropout rate was assumed for each treatment. 
Perspective
• The cost-effectiveness evaluation was conducted from the perspective of the National Health Service (NHS) in Scotland.
Discounting
• A 3.5% annual discount rate was applied to costs and quality-adjusted life-years (QALYs).
Model Inputs
Treatment Efficacy
• In the absence of head-to-head comparisons vs. Scottish Medicines Consortium (SMC)-approved therapies in PsA, network meta-analyses (NMAs), based on published models, 1 were conducted to provide adjusted indirect comparisons and inform the economic model.
• A systematic literature review was undertaken to identify all published evidence on the efficacy, effectiveness, and safety of all treatments considered in the analysis.
• Thirteen randomised, controlled trials, including 4 apremilast trials, were considered for the NMA.
• The mean PsARC response rate was calculated for apremilast and TNF-α inhibitor therapies ( Table 1) . CrI=credible interval.
• A decline in the efficacy of subsequent TNF-α inhibitor therapies in primary TNF-α inhibitor non-responders was assumed, and this decrease was based on the hazard ratio of 2.7 published in . 1 The proportion of long-term withdrawals was also assumed to increase by 36%. 1 • Patients in BSC were assumed to experience placebo response.
Utilities
• The European Quality of Life-Five Dimensions questionnaire (EQ-5D) utilities were obtained as a linear function of the Health Assessment Questionnaire-Disability Index (HAQ-DI) and Psoriasis Area and Severity Index (PASI) scores based on a previously published regression equation (EQ-5D = 0.897 − 0.298 • HAQ-DI -0.004 • PASI).
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• The mean change in HAQ-DI scores by PsARC response for each treatment was derived from the NMA.
• The mean PASI scores, by 75% reduction from baseline PASI (PASI-75) response, were derived from the PASI-50, PASI-75, and PASI-90 response rates and the baseline PASI score using the method specified in Rodgers et al. (2011) ( Table 2) .
• HAQ-DI gain in score was assumed to be maintained for patients responding to active therapy.
• Following entry into BSC for PsARC non-responders, the HAQ-DI was assumed to rebound to baseline and progress over time at a rate of 0.006 per 28-day cycle. 1 In PsARC responders, the HAQ-DI was assumed to improve corresponding to that estimated in the NMA for the placebo responders and then progress over time at the same rate as non-responders. Resource Utilisation
• Treatment dosage, frequency, and mode of administration were based on product labels and other published sources 9 ( Table 3 ).
• 
Costs
• Drug costs were sourced from the British National Formulary (BNF) ( Table 5) , 10 while drug administration costs and the costs associated with physician visits were obtained from the NHS 2012-2013 reference cost schedule. • Other healthcare costs, including resources for secondary care such as hospitalisations, were assumed to increase with the severity of disease and were estimated as a function of the HAQ-DI score.
11
-These costs were applied to patients in both the trial period and the continued use health states, following the methods presented by .
1
-Prescription costs, accounting for 15% of total costs, were excluded to avoid double counting.
-As the above regression function was estimated based on patients with rheumatoid arthritis, psoriasis-related costs were assigned to patients based on whether a PASI-75 response was achieved.
• Similar to the other healthcare costs, costs associated with arthritis in BSC were estimated as a function of the HAQ-DI score.
-Prescription costs were not excluded for these patients, because they were not assumed to have received any additional therapy. Psoriasis-related costs were included.
• All unit costs were inflated to 2012-2013 prices based on the Hospital & Community Health Services Index published in the Personal Social Service Research Unit (2013).
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Analysis of Uncertainty
• Probabilistic sensitivity analyses and deterministic sensitivity analyses were conducted to assess the possible implications of uncertainty.
• The following scenario analyses were also conducted: were estimated using apremilast trial data.
-Alternative costs were estimated for other healthcare costs and BSC (Poole et al.
[2010]). 13 
RESULTS
Base Case
• Apremilast followed by TNF-α inhibitors is a cost-effective strategy over a 40-year time horizon (Table 6 ).
• On average, the time spent with PsARC response was greater among those in the apremilast sequence compared with those in the TNF-α inhibitor sequence (9.34 years vs. 6.85 years).
• The average time spent on TNF-α inhibitor treatments and in BSC was also lower in the apremilast sequence (0.33 years and 2.79 years, respectively). Sensitivity Analysis
• Results suggest that, with the exception of the HAQ-DI score progression when not on treatment, variations in the model parameters do not significantly affect the base case conclusions (Figure 2) , and apremilast is cost-effective based on a willingness-to-pay threshold of £20,000 to £30,000 ( Figure 3 ). Change in HAQ-DI score -Etanercept PsARC responders £0 £5,000 £10,000 £15,000 £20,000 £25,000 £30,000 £35,000 £40,000 £45,000 £50,000
Incremental Cost-effectiveness Ratio Figure 3 . Cost-effectiveness Acceptability Curve 0 £0 £20,000 £40,000 £60,000 £80,000 £100,000 £120,000 £140,000 £160,000 £180,000 £200,000 
Scenario Analysis
• Results from the alternative scenarios also suggest that variations in the model parameters and structural assumptions do not affect the base case conclusions ( Table 7) , and apremilast is cost-effective based on a willingness-to-pay threshold of £20,000 to £30,000. 
LIMITATIONS
• There is a lack of head-to-head trial data for apremilast vs. the identified TNF-α inhibitor comparators.
• Because of the lack of comparative long-term data on treatment withdrawal rates, these data were assumed to remain constant over time.
• Finally, because of the lack of long-term safety data for apremilast, our model did not explicitly incorporate adverse events and costs or disutilities related to these factors.
CONCLUSION
• Apremilast, when used as an additional therapy step in the current treatment pathway before TNF-α inhibitor therapy, is a cost-effective strategy in the treatment of PsA based on a willingness-to-pay threshold of £20,000 to £30,000 in the NHS in Scotland.
Cost-effectiveness of Apremilast in
Psoriatic Arthritis in Scotland 
BACKGROUND
• Psoriatic arthritis (PsA) is a chronic, inflammatory disease that develops in up to 30% of patients with psoriasis. It is characterised by inflammation of both the skin and the axial and peripheral terminal interphalangeal joints. 1 • PsA has an estimated prevalence of 0.3% to 1.0% in the general population and can result in joint damage, decreased physical function, and impaired activities of daily living and disability. [2] [3] [4] [5] • Effective treatment of PsA has been shown to improve patient-reported outcomes significantly. 6 • Apremilast is an oral phosphodiesterase 4 inhibitor that acts intracellularly to regulate inflammatory mediators. 7 • In 2015, the European Medicines Agency approved apremilast, alone or in combination with disease-modifying anti-rheumatic drugs (DMARDs), for the treatment of active PsA in adult patients who have had an inadequate response to or who have been intolerant of a prior DMARD therapy.
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• Treatment dosage, frequency, and mode of administration were based on product labels and other published sources 9 ( Table   3 ).
• Resource use estimates associated with physician visits and routine laboratory tests for adalimumab and etanercept were based on Rodgers et al. (2011), 1 while resource use for apremilast was based on expected clinical practice ( Table   4) .
RESULTS
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• Apremilast followed by TNF-α inhibitors is a cost-effective strategy over a 40-year time horizon ( Table   6 ).
• Results suggest that, with the exception of the HAQ-DI score progression when not on treatment, variations in the model parameters do not significantly affect the base case conclusions ( Figure  2) , and apremilast is cost-effective based on a willingness-to-pay threshold of £20,000 to £30,000 ( Figure   3 ). 
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Model Structure • Different treatment options were considered as mutually exclusive health states and describe the treatment pathway and the impact of each treatment option, as measured by the Psoriatic Arthritis Response Criteria (PsARC), at the end of the trial period, ranging from 12 to 16 weeks.
• All-cause mortality, adjusted to reflect the increased risk of death associated with PsA, was included in all health states. 8
• A 16.5% all-cause annual dropout rate was assumed for each treatment. 1 
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Model Inputs
Treatment Efficacy
• A decline in the efficacy of subsequent TNF-α inhibitor therapies in primary TNF-α inhibitor non-responders was assumed, and this decrease was based on the hazard ratio of 2.7 published in . 1 The proportion of long-term withdrawals was also assumed to increase by 36%. 1 • Patients in BSC were assumed to experience placebo response. • The mean change in HAQ-DI scores by PsARC response for each treatment was derived from the NMA.
• The mean PASI scores, by 75% reduction from baseline PASI (PASI-75) response, were derived from the PASI-50, PASI-75, and PASI-90 response rates and the baseline PASI score using the method specified in Rodgers et al. (2011) ( Table 2 ). 1
• Resource use estimates associated with physician visits and routine laboratory tests for adalimumab and etanercept were based on Rodgers et al. (2011), 1 while resource use for apremilast was based on expected clinical practice ( Table 4) . 
Costs
• Drug costs were sourced from the British National Formulary (BNF) ( • Other healthcare costs, including resources for secondary care such as hospitalisations, were assumed to increase with the severity of disease and were estimated as a function of the HAQ-DI score.
-These costs were applied to patients in both the trial period and the continued use health states, following the methods presented by . 1 -Prescription costs, accounting for 15% of total costs, were excluded to avoid double counting.
-As the above regression function was estimated based on patients with rheumatoid arthritis, psoriasis-related costs were assigned to patients based on whether a PASI-75 response was achieved. 1 • Similar to the other healthcare costs, costs associated with arthritis in BSC were estimated as a function of the HAQ-DI score. 1 -Prescription costs were not excluded for these patients, because they were not assumed to have received any additional therapy. Psoriasis-related costs were included.
• All unit costs were inflated to 2012-2013 prices based on the Hospital & Community Health Services Index published in the Personal Social Service Research Unit (2013). 12 
Analysis of Uncertainty
• The following scenario analyses were also conducted: -Alternative costs were estimated for other healthcare costs and BSC (Poole et al.
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Apremilast
One outpatient visit at baseline followed by a revisit at Month 3 and then twice yearly
Self-administered
Clinical expert opinion
Adalimumab
One outpatient visit at baseline followed by a revisit at Month 3 and then twice yearly 
Costs
• Drug costs were sourced from the British National Formulary (BNF) ( Table 5) , 10 while drug administration costs and the costs associated with physician visits were obtained from the NHS 2012-2013 reference cost schedule. 11 10 • Costs associated with laboratory tests were taken from those reported in . 1 • Other healthcare costs, including resources for secondary care such as hospitalisations, were assumed to increase with the severity of disease and were estimated as a function of the HAQ-DI score.
Analysis of Uncertainty
• The following scenario analyses were also conducted: -Alternative costs were estimated for other healthcare costs and BSC ). 13 
RESULTS
Base Case
• Results suggest that, with the exception of the HAQ-DI score progression when not on treatment, variations in the model parameters do not significantly affect the base case conclusions (Figure 2) , and apremilast is cost-effective based on a willingness-to-pay threshold of £20,000 to £30,000 ( Figure 3) . Change in HAQ-DI score -Etanercept PsARC responders £0 £5,000 £10,000 £15,000 £20,000 £25,000 £30,000 £35,000 £40,000 £45,000 £50,000
Scenario Analysis
LIMITATIONS
CONCLUSION
Costs
Analysis of Uncertainty
• The following scenario analyses were also conducted:
-Number of anti-TNF-α options in the treatment sequence: § Scenario 1: apremilast → adalimumab → BSC vs. adalimumab → BSC § Scenario 2: apremilast → adalimumab → etanercept → golimumab → BSC vs. adalimumab → etanercept → golimumab → BSC -Utilities obtained from regression function (EQ-5D = 0.833 − 0.261 • HAQ-DI -0.002 • PASI) were estimated using apremilast trial data.
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